Print Page  |  Close Window

Investor Overview

Corporate Profile

Oncobiologics is a clinical stage biopharmaceutical company focused on identifying, developing, manufacturing and commercializing complex biosimilar therapeutics. Our current focus is on technically challenging and commercially attractive monoclonal antibodies (mAbs), in the disease areas of immunology and oncology. Our strategy is to leverage our BioSymphony™ Platform to cost-effectively develop these biosimilars on an accelerated timeline, which is fundamental to our success and we believe positions us to be a leading biosimilar company.

Latest News

July 19, 2018

Oncobiologics Completes Exchange of Series A Convertible Preferred Stock for Newly Created Series A-1 Convertible Preferred Stockmore >

July 11, 2018

Oncobiologics Regains Compliance with Applicable Nasdaq Listing Requirementsmore >

June 20, 2018

Oncobiologics Announces Conversion of Majority of Series A Convertible Preferred Stockmore >

Upcoming Events

There are currently no events scheduled.